Dr. Chen Su joined Eli Lilly and company as a senior biologist in 2000 and was promoted to principal research scientist in 2003. She received her Ph.D. in computational biology in 2000 from Penn State, where she established relationships between genetic polymorphism of immune system genes and immune functions. She earned her B.S. in biochemistry and molecular biology from Beijing University in 1995. Dr. Su has focused on combining computational, statistical, and biological approaches to analyze genomic, proteomic, and physiological data in large-scale genomics experiments. She has successfully applied these methodologies to support multiple discovery programs, toxicology studies, and clinical trials. Her work has contributed to increased efficiency of bench labs; identification of novel drug targets; and putative biomarkers for obesity, cancer, and toxicology. Dr. Su currently leads several multidisciplinary efforts in biomarker identification and drug mechanisms of action. Dr. Su holds a publication record with 21 peer-reviewed original research papers and numerous conference presentations. She has won multiple prestigious awards from Lilly Research Laboratories and has been invited to teach at Lilly University and major academic institutes. She is also the recipient of '2004 Young Innovator' awarded by the Science Spectrum magazine.